P102 Outcomes of coronavirus disease 2019 among patients with inflammatory bowel diseases and the influence of IBD-related medications– A Danish prospective population-based cohort study
Attauabi, M.(1,2,3);Poulsen, A.(4);Kajbæk Verner-Andersen, M.(5);Rosager Hansen, M.(6);Pedersen, N.(7);Pilegaard Prahm, A.(4);Berg Lødrup, A.(8);Haderselv, K.(9);Larsen, L.(10);Jess, T.(10,11);Glerup, H.(12);Molazahi, A.(13);Mathiassen Oppfeldt, A.(14);Dahlerup, J.F.(15);Lodberg Hvas, C.(15);Neumann, A.(16);Wase, A.(16);Dam Jensen, M.(17);Nathan, T.(17);Jensen, S.(17);Theede, K.(1,3);Kiszka-Kanowitz, M.(1,3);Benedict Seidelin, J.(2);Burisch, J.(1,3);
(1)Hvidovre University Hospital, Gastrounit- Medical Section, Hvidovre, Denmark;(2)Herlev University Hospital, Department of Gastroenterology and Hepatology, Herlev, Denmark;(3)University of Copenhagen- Hvidovre Hospital, Copenhagen center for inflammatory bowel disease in children- adolescents and adults, Hvidovre, Denmark;(4)Bispebjerg University Hospital, Digestive Disease Center, Copenhagen, Denmark;(5)Zealand University Hospital, Department of Internal Medicine, Koege, Denmark;(6)North Zealand University Hospital, Department of Gastroenterology, Frederikssund, Denmark;(7)Slagelse Hospital, Department of Gastroenterology, Slagelse, Denmark;(8)Region Hospital West Jutland- Herning, Department of Internal Medicine, Herning, Denmark;(9)Rigshospitalet- Copenhagen University Hospital, Department of Gastroenterology, Copenhagen, Denmark;(10)Aalborg University Hospital, Department of Gastroenterology and Hepatology, Aalborg, Denmark;(11)Statens Serum Institut, Department of Epidemiology Research, Copenhagen, Denmark;(12)Region Hospital Silkeborg, Department of Internal Medicine, Silkeborg, Denmark;(13)Holbaek Hospital, Department of Internal Medicine, Holbaek, Denmark;(14)Region Hospital Horsens, Department of Internal Medicine, Horsens, Denmark;(15)Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark;(16)Region Hospital Viborg, Department of Internal Medicine, Viborg, Denmark;(17)Lillebaelt Hospital, Department of Internal Medicine- Section of Gastroenterology, Vejle, Denmark; the Danish COVID-IBD Study Group
Population-based data regarding outcomes of coronavirus disease 2019 (COVID-19) among patients with ulcerative colitis (UC) and Crohn’s disease (CD) are limited. Studies on the association of COVID-19 outcomes and immunomodulating therapies, are scarce. Therefore, we aimed to conduct a population-based study investigating the outcomes of COVID-19 among patients with UC and CD in Denmark.
The Danish COVID-19 IBD Database is an extensive population-based database that prospectively monitors the disease course of laboratory-confirmed COVID-19 among patients with UC and CD in Denmark. Severe COVID-19 was defined as COVID-19 necessitating intensive care unit admission, ventilator use, or death. Regression analysis was adjusted for age, sex, disease type, disease activity, cardiovascular disease, and corticosteroids.
The study recruited 363 patients (UC: 223; CD: 140) from January 28th, 2020, to February 7th, 2021. A total of 36 (16.1%) and 18 (12.9%) patients with UC and CD, respectively, required a COVID-19 related hospitalization, while eight (3.6%) and three (2.1%) patients required intensive care treatment. Death due to COVID-19 was observed among eight (3.6%) and two (1.4%) patients, respectively. The association between these outcomes and IBD-related treatment is presented in Table 1. As shown, none of the IBD-related medications were associated with severe COVID-19 in univariate and adjusted analysis. However, systemic steroids were found to be associated with the risk of COVID-19 related hospital admission among patients with UC (adjusted odds ratio (aOR)=6.54 (95% CI 1.09-36.39)) and CD (aOR=5.45 (95% CI 2.07-12.24)).
This ongoing Danish population-based study on COVID-19 outcomes among patients with UC and CD demonstrated severe COVID-19 among only a minority of patients, which was not associated with IBD-related medications. However, use of systemic steroids were associated with COVID-19 necessitating hospital admission among patients with UC and CD.